ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS

Isis Pharmaceuticals has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of ALS. About 20% of inherited ALS cases are caused by a mutant form of the SOD1 gene–ISIS-SOD1Rx is therefore designed to reduce the body’s production of SOD1. The trial is supported in part by the ALS Association and the MDA.

Click here to read more.

Share this: